Berencsi Klara, Meropol Neal J, Hoffman John P, Sigurdson Elin, Giles Lydia, Rani Pyapalli, Somasundaram Rajasekharan, Zhang Tianqian, Kalabis Jiri, Caputo Laura, Furth Emma, Swoboda Rolf, Marincola Francesco, Herlyn Dorothee
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA.
Cancer Immunol Immunother. 2007 Mar;56(3):359-70. doi: 10.1007/s00262-006-0190-2. Epub 2006 Jun 17.
Adoptive immunotherapy of cancer patients with cytolytic T lymphocytes (CTL) has been hampered by the inability of the CTL to home into tumors in vivo. Chemokines can attract T lymphocytes to the tumor site, as demonstrated in animal models, but the role of chemokines in T-lymphocyte trafficking toward human tumor cells is relatively unexplored. In the present study, the role of chemokines and their receptors in the migration of a colon carcinoma (CC) patient's CTL toward autologous tumor cells has been studied in a novel three-dimensional organotypic CC culture. CTL migration was mediated by chemokine receptor CXCR3 expressed by the CTL and CXCL11 chemokine secreted by the tumor cells. Excess CXCL11 or antibodies to CXCL11 or CXCR3 inhibited migration of CTL to tumor cells. T cell and tumor cell analyses for CXCR3 and CXCL11 expression, respectively, in ten additional CC samples, may suggest their involvement in other CC patients. Our studies, together with previous studies indicating angiostatic activity of CXCL11, suggest that CXCL11 may be useful as an immunotherapeutic agent for cancer patients when transduced into tumor cells or fused to tumor antigen-specific Ab.
用细胞溶解性T淋巴细胞(CTL)对癌症患者进行过继性免疫治疗,一直因CTL在体内无法归巢至肿瘤部位而受到阻碍。正如在动物模型中所证实的,趋化因子可将T淋巴细胞吸引至肿瘤部位,但趋化因子在T淋巴细胞向人类肿瘤细胞迁移过程中的作用相对而言尚未得到充分研究。在本研究中,在一种新型的三维器官型结肠癌(CC)培养体系中,对趋化因子及其受体在一名CC患者的CTL向自体肿瘤细胞迁移中的作用进行了研究。CTL迁移是由CTL表达的趋化因子受体CXCR3以及肿瘤细胞分泌的CXCL11趋化因子介导的。过量的CXCL11或针对CXCL11或CXCR3的抗体可抑制CTL向肿瘤细胞的迁移。对另外10份CC样本分别进行T细胞和肿瘤细胞的CXCR3和CXCL11表达分析,可能提示它们在其他CC患者中也发挥作用。我们的研究,连同之前表明CXCL11具有血管生成抑制活性的研究,提示当CXCL11被转导至肿瘤细胞或与肿瘤抗原特异性抗体融合时,它可能作为一种免疫治疗剂用于癌症患者。